昊帆生物 reported revenue of ¥0.38B for the period ended 2026-06-30, +40.3% year on year. Net income was ¥0.07B, a 18.3% net margin on a 35.4% gross margin. The largest revenue line is 多肽合成试剂 at 70% of the total. Free cash flow for the period was ¥-0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.38B | +40.3% |
| Gross profit | ¥0.13B | — |
| Operating income | ¥0.08B | — |
| Net income | ¥0.07B | -8.6% |
| Gross margin | 35.4% | Net margin 18.3% |
| Revenue Q/Q | +20.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| 多肽合成试剂 | ¥0.26B | 69.6% |
| 通用型分子砌块 | ¥0.05B | 14.0% |
| 原料药、医药中间体等 | ¥0.03B | 7.7% |
| 蛋白质试剂 | ¥0.03B | 7.1% |
| 其他 | ¥0.01B | 1.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.24B | 64.6% |
| R&D | ¥0.02B | 6.2% |
| SG&A | ¥0.03B | 8.8% |
| Tax & other | ¥0.01B | 3.2% |
| Item | Amount |
|---|---|
| Total assets | ¥2.88B |
| Total liabilities | ¥0.47B |
| Shareholders' equity | ¥2.41B |
| Equity / assets | 83.5% |
| Operating cash flow | ¥0.05B |
| Capital expenditure | ¥0.10B |
| Free cash flow | ¥-0.05B |
| Cash conversion (OCF / net income) | 183% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
仁信新材 ・ 宏景科技 ・ 溯联股份 ・ 星源卓镁 ・ 英特科技 ・ 华人健康 ・ 安培龙 ・ 协昌科技 ・ 阿莱德 ・ 波长光电 ・ 世纪恒通 ・ 森泰股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies